Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;40(4):811-827.
doi: 10.1016/j.ccm.2019.08.001.

New Drugs for the Treatment of Tuberculosis

Elisa H Ignatius  1 , Kelly E Dooley  2
Affiliations
Review

New Drugs for the Treatment of Tuberculosis

Elisa H Ignatius et al. Clin Chest Med. 2019 Dec.

Abstract

Tuberculosis (TB) has now surpassed HIV as the leading infectious cause of death, and treatment success rates are declining. Multidrug-resistant TB, extensively drug-resistant TB, and even totally drug-resistant TB threaten to further destabilize disease control efforts. The second wave in TB drug development, which includes the diarylquinoline, bedaquiline, and the nitroimidazoles delamanid and pretomanid, may offer options for simpler, shorter, and potentially all-oral regimens to treat drug-resistant TB. The "third wave" of TB drug development includes numerous promising compounds, including less toxic versions of older drug classes and candidates with novel mechanisms of action.

Keywords: Bedaquiline; Delamanid; New drugs; Pharmacology; Pretomanid; Tuberculosis.

PubMed Disclaimer

References

    1. World Health Organization (WHO). Global tuberculosis report 2018. WHO; 2018. Geneva (Switzerland).
    1. Kendall EA, Shrestha S, Cohen T, et al. Priority-setting for novel drug regimens to treat tuberculosis: an epidemiologic model. PLoS Med 2017; 14(1):e1002202. - PMC - PubMed
    1. Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med 2018;24(11):1708–15. - PMC - PubMed
    1. Slomski A. South Africa warns of emergence of “totally” drug-resistant tuberculosis. JAMA 2013; 309(11):1097–8. - PubMed
    1. Dheda K, Limberis JD, Pietersen E, et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med 2017; 5(4):269–81. - PubMed

Publication types

MeSH terms